v3.26.3
Note 7 - Commitments and Contingencies (Details Textual)
3 Months Ended 12 Months Ended
Apr. 30, 2026
USD ($)
Sep. 27, 2022
USD ($)
Jul. 31, 2026
USD ($)
Dec. 31, 2023
USD ($)
$ / shares
Jan. 31, 2026
Sep. 20, 2023
Dec. 31, 2013
USD ($)
Lessee, Operating Lease, Extension Term (Month)   64 months          
Lessee, Operating Lease, Monthly Payments   $ 13,129          
Lessee, Operating Lease, Annual Rent Increase   3.00%          
Operating Lease, Expense     $ 35,000        
Lessee, Operating Lease, Discount Rate         12.00%    
Loss Contingency, Damages Sought, Value $ 180,000            
Technology Agreement [Member]              
Aggregate Payment of Royalties       $ 3,000,000      
Closing Quoted Share Price (in dollars per share) | $ / shares       $ 6,875      
Accrued Royalty Payment Benchmark       $ 3,500,000      
License Agreements [Member]              
Number of License Agreements           11  
Number of AI Cardiovascular Algorithms           13  
Number of Data Science Methods           2  
Number of Filed Patents           3  
First 2400 MyoVista Devices [Member] | Technology Agreement [Member]              
Royalty Payment Upon Sale of Devices             $ 500
Royalty Payment, Number of Devices to Sell             2,400
Devices After 2400 Until 3500000 is Paid [Member] | Technology Agreement [Member]              
Royalty Payment Upon Sale of Devices       200      
Royalty Expense       $ 3,500,000